Person
Feng, Hui
|
|
Biography and Research Interest
Dr. Feng's Research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia. The research strategy of Dr. Feng’s laboratory is to combine the analysis of human cancer genomic databases with the genetic and imaging capacities of the zebrafish system.
Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers andto characterize their molecular relevance to MYC.
The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.
Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers andto characterize their molecular relevance to MYC.
The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.
Non-Zebrafish Publications
Hui Feng, Weiwei Zhong, George Punkosdy, Subin Gu, Liang Zhou, Erin K. Seabolt, and Edward T. Kipreos. 1999. CUL-2 is required for the G1-to-S phase transition and mitotic chromosome condensation in
Caenorhabditis elegans. Nature Cell Biology 1: 486-492.
Weiwei Zhong, Hui Feng, Fernando Santiago, and Edward T. Kipreos. 2003. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA replication licensing. Nature 423: 885-889.
Hui Feng and Edward T. Kipreos, 2003. Preventing DNA re-replication: Lessons learned from Yeasts, Worms, and Vertebrates. Landes Bioscience, Cell Cycle 2(5): 431-434.
Jihyun Kim, Hui Feng, Edward T. Kipreos. 2007. C. elegans CUL-4 prevents re-replication by promoting the nuclear export of CDC-6 via a CKI-1-dependent pathway. Current Biology 17(11):966-72, PMCID: PMC1945017.
Dimple R. Bosu, Hui Feng, Kyoengwoo Min, Youngjo Kim, Matthew R. Wallenfang, and Edward T. Kipreos. 2010. C. elegans CAND-1 regulates cullin neddylation, cell proliferation and morphogenesis in specific tissues. Developmental Biology. 346(1):113-26, PMCID: PMC2955628.
Nicole M. Anderson¶, Itrat Harrold¶, Marc R. Mansour, Takaomi Sanda, Michael McKeown, Nicholas Nagykary, James E. Bradner, Guang Lan Zhang, A Thomas Look and Hui Feng. 2013. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more differentiated T-ALL cell lines. Leukemia (Accepted). ¶equal contribution.